Myxedema Coma Market Size

Myxedema Coma Market size was valued at USD 2.09 Billion in 2023 and is projected to exceed USD 3.7 Billion by the end of 2036, expanding at over 4.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of myxedema coma is evaluated at USD 2.17 Billion. The reason behind the growth is impelled by a higher prevalence of diabetes 1. Type 1 diabetes could be linked to other diseases including Hashimoto’s thyroiditis, which is considered a major cause of hypothyroidism. Moreover, it causes damage to the thyroid gland and may reduce the level of thyroid hormones in the body. Globally, there were approximately 7 million people with type 1 diabetes in 2021.

The growing geriatric population is believed to fuel the myxedema coma market growth. The elderly population is more prone to thyroid dysfunction and other age-related diseases such as diabetes which may increase the risk of myxedema coma. Lately, over 8% of the world's population, is over the age of 65, and by 2050, this ratio is anticipated to rise to around 15%.